Unichem Laboratories Limited

Usv Private Limited

Council of Scientific and Industrial Research

Health Science Funding, LLC

Dhananjay Govind Sathe

Arijit Das

Yashwant S Surve

Ramdas Ahire

Venkatasubramanian Radhakrishnan Tarur

Kamlesh Digambar Sawant

Tushar Anil Naik

Pravin Kumar Maurya

Yogesh Subhash Patil

Sanjay Raikar

Srikant V Pimple

Bhushan Sudhakar Pandit

Harish Kashinath Mondkar

Ankush Sampat Kekan

Samadhan Daulat Patil

Umesh Parashram Aher

Dnyaneshwar V Gawas

Nilesh L Bonde

Avinash Venkatraman Naidu

Sudeep Kumar

Mukund Keshao Gurjar

Divya Lal Saksena

Deepak Anant Hegde

Varsha Shashank Choudhary

Yogesh Sharad Bhide

Rakesh Shekhawat

Sanjay Janardhan Naik

Rajesh Ganpat Bhopalkar

Bhavesh B Patel

Sukumar Ramanujam

Pradeep Kumar Gupta

Sanjay Vyankatrao Patil

Subhash Vishwanath Damle

Dipak Subhash Patil

Parag Sukumar Gatne

Sasikumar Mohan Thoovara

Rahul Bhagwatkar

Narayana Rao Mantripragada

Ashok Govind Matale

Gautam Ramjibhai Patel

Manoj Madhukarrao Deshpande

Eknath Kamalakar Kshirsagar

V R Tarur

Sanjay Bhaskar Chowkekar

Madhusudan Nagorao Deshmukh

Vincent Paul

Venkatasubramaniam Radhakrishnan Tarur

Vishal Kulkarni

Jotirling Ramling Mali

Santosh Pratap Pardeshi

Sashikant D Metkar

Tushar Patil

Dhananjay Pramod Tattu

Milind Vinayak Sathe, Sr

Venkatasubramanian Radhakrishna Tarur

Prafulla Nagawade

Subramanian Sundaram

Harish Kashniath Mondkar

Anindya Sibnath Bhattacharyya

Avinash Venkataraman Naidu

Vishal Jadhav

Bijay Kumar Padhi

Mamata Katdare

Sundaram Subramanian

Ramanujam Sukumar

Ramdas N Ahire

The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:1, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purification of recombinant lectin having amino acid sequence of SEQ ID NO: 1.

Process for the preparation of recombinant lectin protein

A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homology thereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrate binding site; at least one amino acid modification in the N-terminus; at least one amino acid modification at position 76; or at least one amino acid modification at position 44 or 89. The modified lectin protein does not consist of the amino acid sequence of any of SEQ ID NOs: 2 to 4.

Recombinant lectin variants

The present invention relates to the novel key intermediate, 4-{4-[(SS)-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, m the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method of preparing rivaroxaban using this novel intermediate. The invention provides an improved and efficient process for preparation of Rivaroxaban.

Process for the preparation of Rivaroxaban involving novel intermediate

The present disclosure relates to a stable, reproducible and bioequivalent apixaban compositions, wherein the composition comprising apixaban having a Dparticle size of more than 100 microns, preferably between 300 and 1000 microns, and more preferably between 350 and 800 microns, and further comprising one or more pharmaceutically acceptable excipients. The present disclosure further provides a process for preparation of a pharmaceutical composition comprising apixaban by wet granulation.

Pharmaceutical composition of apixaban

A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. A pharmaceutical composition containing cinacalcet or pharmaceutically acceptable salts thereof having a particle size distribution Dequal to or less than 20 &#x3bc;m, Dequal to or less than 10 &#x3bc;m, and Dequal to or less than 5 &#x3bc;m and one or more and binders in an amount of 0.9% w/w or less, relative to the total weight of composition, where the composition is not free of binder and that the total amount of binder does not exceed 0.9% w/w relative to the total weight of the composition.

Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders

The present invention relates to a disintegrant free pharmaceutical composition comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. Particularly the present invention relates to disintegrant free immediate release dosage form comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to process of preparing such composition and its use in psoriatic arthritis and psoriasis.

Pharmaceutical compositions of apremilast

The present invention relates to the novel key intermediate, 4-{4-[(5S)-(Aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, in the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method of preparing rivaroxaban using this novel intermediate. The invention provides an improved and efficient process for preparation of Rivaroxaban.

Process for the preparation of rivaroxaban involving novel intermediate

The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200&#x3bc;, D50 35-90&#x3bc; and D5 7-30&#x3bc; as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200&#x3bc;, D50 35-90&#x3bc; and D5 7-30&#x3bc; and one or more pharmaceutically acceptable excipient. It is produced by wet granulation techniques.

Bioequivalent pharmaceutical composition of vortioxetine hydrobromide

An alternative and improved process for the preparation of Apremilast (Formula I) and Apremilast form B or a pharmaceutically acceptable salt thereof is provided. The novel process includes hydrogenation in acetone, Cyclization and acetylation followed by condensation in methyl isobutyl ketone (MIBK) and acetic acid mixture in specific volume ratios.

Process to prepare n-[2-[(1s)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulphonyl) ethyl]-1, 3-dioxo-2,3-dihydro-1h-isoindol-4yl]acetamide

The present invention is related to an improved process for the preparation and purification of crystalline Vortioxetine hydrobromide of Formula-I. The process according to present invention is operationally simple and suitable for industrial application which will avoid hazardous chemicals and eliminate column chromatography to get ICH quality of pharmaceutically acceptable active pharmaceutical ingredient having snow white appearance.

Process for preparation and purification of vortioxetine hydrobromide

The present disclosure is related to an improved and efficient process for preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine which comprises: (a) N-acylation of 3-Amino-4-methyl pyridine; (b) Quarternization of 3-Acetylamino-4-methyl pyridine using benzyl halide; (c) Partial reduction of quarternized 3-Acetylamino-4-methyl pyridine by Sodium borohydride in Methanol or water; (d) Hydrolysis of partially reduced product to 1-Benzyl-4-methylpiperidin-3-one in presence of acid; (e) Reductive amination of 1-Benzyl-4-methylpiperidin-3-one using Methanolic methylamine in presence of Titanium(IV) isopropoxide in Methanol; (f) Resolution of 1-Benzyl-4-methylpiperidin-3-yl)-methylamine using Ditoluoyl (L) tartaric acid to get (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine. The disclosure is also related to novel intermediates: wherein R, R' and X are as described in the specification.

Process for the preparation of (3R,4R)-(1-benzyl-4-methylpiperidin-3-yl)-methylamine

The present invention relates to an improved process for the synthesis of (R)-Lacosamide in which free base of O-methyl-N-benzyl-D-Serinamide is not isolated before acylation. The process avoids the use of column chromatography and chiral resolution for the preparation of different stages of Lacosamide.

Process for the preparation of lacosamide

The present invention refers to novel process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for preparation of Apixaban using a different sequence of synthetic steps and does not involve use of Ullmann reaction.

Process for the preparation of apixaban and intermediates thereof

A process for the preparation of Ranolazine (I) and its acid addition salts and the process for the preparation of compound of formula (7). 

Process for the preparation of ranolazine

Process for the preparation of Apixaban and intermediates thereof

Growing community of inventors

Maharashtra, India

Dhananjay Govind Sathe